Combination strategy to circumvent the acquired resistance to VEGF receptor tyrosine kinase inhibitor in M24met melanoma in mice

被引：0
|
作者：
Zhang, Lianglin [1 ]
Lira, Maruja E. [1 ]
Ching, Keith A. [1 ]
Chen, Enhong [1 ]
Lu, Tina [1 ]
Christensen, James G. [1 ]
Hu-Lowe, Dana D. [1 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-3270
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3270
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
    Fujino, Toshio
    Mitsudomi, Tetsuya
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (03):
  • [2] MET signaling in acquired resistance to irreversible EGF receptor tyrosine kinase inhibitors
    不详
    PHARMACOGENOMICS, 2010, 11 (06) : 745 - 746
  • [3] The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
    Rachna T Shroff
    Mark Yarchoan
    Ashley O'Connor
    Denise Gallagher
    Marianna L Zahurak
    Gary Rosner
    Chimela Ohaji
    Susan Sartorius-Mergenthaler
    Vivek Subbiah
    Ralph Zinner
    Nilofer S Azad
    British Journal of Cancer, 2017, 116 : 1402 - 1407
  • [4] The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
    Shroff, Rachna T.
    Yarchoan, Mark
    O'Connor, Ashley
    Gallagher, Denise
    Zahurak, Marianna L.
    Rosner, Gary
    Ohaji, Chimela
    Sartorius-Mergenthaler, Susan
    Subbiah, Vivek
    Zinner, Ralph
    Azad, Nilofer S.
    BRITISH JOURNAL OF CANCER, 2017, 116 (11) : 1402 - 1407
  • [5] Targeting aurora kinase b overcomes acquired resistance to met-tyrosine kinase inhibitor in met-amplified lung cancer
    Choi, Yura
    Hwang, Mihwa
    Kim, Sunshin
    Song, Jae J.
    Lee, Youngjoo
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Chang, Youjin
    Kim, Seon Ye
    Choi, Yun Jung
    So, Kwang Sup
    Rho, Jin Kyung
    Kim, Woo Sung
    Lee, Jae Cheol
    Chung, Jin-Haeng
    Choi, Chang-Min
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2013, 75 (03) : 95 - 103
  • [7] Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
    Rachna T Shroff
    Mark Yarchoan
    Ashley O'Connor
    Denise Gallagher
    Marianna L Zahurak
    Gary Rosner
    Chimela Ohaji
    Susan Sartorius-Mergenthaler
    Rose Parkinson
    Vivek Subbiah
    Ralph Zinner
    Nilofer S Azad
    British Journal of Cancer, 2018, 118 : e2 - e2
  • [8] Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib
    Haura, E.
    Gao, J.
    Li, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 182 - 182
  • [9] Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice
    Kang, Seungbum
    Roh, Young-Jung
    Kim, In-Beom
    EXPERIMENTAL EYE RESEARCH, 2013, 112 : 125 - 133
  • [10] MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.
    Beeram, Muralidhar
    Patnaik, Amita
    Amaravadi, Ravi K.
    Haas, Naomi B.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Smith, Lon S.
    Harlacker, Kathleen
    Espino, Guillermo
    Drouin, Michel A.
    Tawashi, Manal
    Wang, James
    Karam, Andre
    Hunt, Wendy
    Maroun, Christiane R.
    Fournel, Marielle
    Mehran, Mariam
    Besterman, Jeffrey M.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345